The Drug Administration of Vietnam (Ministry of Health) has sent an official dispatch to the health departments of provinces and cities to recall Femancia hard capsules (elemental iron in the form of ferrous fumarate 305 mg) 100 mg due to poor quality.
The Drug Administration of Vietnam (Ministry of Health) has sent an official dispatch to the health departments of provinces and cities to recall Femancia hard capsules (elemental iron in the form of ferrous fumarate 305 mg) 100 mg due to poor quality.
Specifically, Femancia hard capsules (elemental iron in the form of ferrous fumarate 305 mg) 100 mg; Folic Acid 350 mcg), GĐKLH number: VD-27929-17, batch number: 031222, NSX: 2-12-22, HD: 2-12-25 and batch number 020223, NSX: 21-2-23, HD: 21-2-26 are manufactured by Me Di Sun Pharmaceutical Joint Stock Company (address: 521 An Loi quarter, Hoa Loi ward, Ben Cat town, Binh Duong province).
 |
| Illustration |
The reason for the recall is that the drug sample does not meet quality standards in terms of quantitative indicators and solubility. Therefore, the Drug Administration of Vietnam notifies the health departments of provinces and cities to recall the above drug nationwide; at the same time, inspect, monitor and handle violating units according to current regulations...
It is known that the main ingredient of Femancia hard capsules is elemental iron (in the form of ferrous fumarate 305 mg). The drug is effective in treating cases of anemia due to lack of supply or loss of iron and blood-forming factors.
It is known that in recent years, the use of poor quality drugs has become an increasingly serious problem for public health.
Substandard drugs not only directly affect the health of users but also threaten people's trust in the health system. To protect public health and improve the quality of treatment, recalling substandard drugs is an urgent requirement.
Poor quality drugs can be understood as drugs that do not fully meet the standards of ingredients, effects, safety or do not ensure the production process according to the regulations of the health authority. These products may be defective due to the production, storage, transportation process or due to the supplier's lack of responsibility in quality control.
Typical examples include counterfeit drugs, drugs of unknown origin, or drugs that have been contaminated during the manufacturing process. In addition, some drugs are mixed with foreign substances, making them ineffective or causing serious side effects.
Using poor quality drugs can have serious consequences for patients. Substandard drugs can reduce the effectiveness of treatment, leading to no improvement or worsening of the disease. Poor quality drugs can even cause dangerous side effects, allergies, poisoning or long-term health problems.
This is especially dangerous for patients being treated for chronic diseases, the elderly, children, pregnant women or people with weakened immune systems.
Studies have shown that the use of substandard drugs can lead to serious complications, increased mortality, or increased costs of medical treatment.
Recalling substandard drugs is a necessary step to protect public health. Governments, drug regulatory agencies, and health organizations need to take strict measures to inspect and monitor drugs on the market. When drugs are found to be substandard, timely recall is the most effective solution to stop using these dangerous products.
In fact, there have been many cases of poor quality drugs being recalled, but this process needs to be carried out quickly, synchronously and with close coordination between authorities, businesses and people. Drug recall measures need to be applied not only to imported products but also to domestically produced products.
To prevent the spread of poor quality drugs on the market, authorities need to strengthen inspection, supervision, and strictly handle units that produce and distribute substandard drugs. At the same time, it is necessary to promote propaganda and educate the community about the dangers of using drugs of unknown origin.
Drug manufacturers also need to improve the quality of their products by strictly complying with regulations on drug production and quality control.
Health systems and doctors need to increase counseling and explanation to patients about prescribed drugs, and guide people to identify low-quality drugs.
Regarding drug quality, according to the World Health Organization (WHO), about 11% of medicines in developing countries are counterfeit and may be the cause of death for tens of thousands of children each year from diseases such as malaria or pneumonia.
Through 100 studies involving 48,000 medicines, experts concluded that among counterfeit medicines, malaria and infection drugs accounted for nearly 65%.
In Vietnam alone, the recent situation of counterfeit and poor quality drugs has caused many people to worry. Statistics from the Central Institute for Drug Control show that in 2021, the national testing system tested the quality of over 500 new pharmaceutical active ingredients and 300 medicinal herbs; 338 samples were found to be substandard.
Specifically, 118/28,659 domestic drug samples did not meet quality standards (accounting for 0.41%) and the rate for imported drugs was 26/3,042 foreign drugs (accounting for 0.86%). In addition, through testing, 20 drug samples suspected of being counterfeit drugs were detected, an increase of 11 samples compared to the same period last year.
It is known that the National Strategy for the Development of the Vietnamese Pharmaceutical Industry to 2030 and Vision to 2045 sets the goal that by 2030, 100% of drugs will be proactively and promptly supplied for disease prevention and treatment needs; ensuring drug security, meeting the requirements of national defense, security, disease prevention and control, overcoming the consequences of natural disasters, catastrophes, public health incidents and other urgent drug needs.
Domestically produced drugs strive to meet about 80% of the demand for use and 70% of the market value. Continue to strive to achieve the goal of producing 20% of the demand for raw materials for domestic drug production. Domestically produced vaccines meet 100% of the demand for expanded immunization and 30% of the demand for service immunization.
Vietnam strives to become a center for high-value pharmaceutical production in the region. Receive technology transfer, coordinate processing and technology transfer to produce at least 100 original branded drugs, vaccines, biological products including similar biological products and some drugs that Vietnam cannot produce yet.
Source: https://baodautu.vn/thu-hoi-toan-quoc-vien-nang-cung-femancia-khong-dat-chat-luong-d251240.html
Comment (0)